NCT02689453View on ClinicalTrials.gov

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 19, 2017

Primary Completion Date

June 15, 2021

Study Completion Date

June 15, 2021

Conditions
T-Cell Lymphoma RelapsedAdult T-Cell Leukemia (ATL)Peripheral T-Cell Lymphoma (PTCL)Cutaneous T Cell Lymphoma (CTCL)T-Cell Prolymphocytic Leukemia
Interventions
BIOLOGICAL

IL-15 plus

Recombinant Human IL-15 (subcutaneous (s.c.) rhIL-15) by s.c. injection Monday-Friday over two weeks.

BIOLOGICAL

alemtuzumab

Alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02689453 - Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) | Biotech Hunter | Biotech Hunter